(Reuters) – CTI BioPharma Corp said on Monday the U.S. Food and Drug Administration approved its drug Vonjo (pacritinib) for treating adult patients with a type of bone marrow cancer who also have low blood platelet count.
The nod makes it the third approved drug for the disease.
(Reporting by Mrinalika Roy and Rachna Dhanrajani in Bengaluru; editing by Uttaresh.V)
